ARW vs PLXS

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant concerns in profitability, leverage, and operating efficiency. Despite this, the company shows resilience through solid revenue growth (13% YoY), consistent earnings beats (25.62% average surprise over last 4 quarters), and a reasonable Debt/Equity ratio of 0.48. Valuation appears attractive relative to peers with a P/E of 13.08 versus sector average of 89.76 and a Price/Book under 1, though low margins and declining recent EPS growth (-0.8% QoQ) temper optimism. The stock trades below its Graham Number ($157.92) and intrinsic value estimate ($212.3), suggesting potential undervaluation, but weak profitability metrics and lack of Altman Z-Score data limit confidence in financial stability.

PLXS exhibits exceptional financial health with a perfect Piotroski F-Score of 9/9 and a very low Debt/Equity ratio of 0.13. However, the stock is significantly overvalued, trading at $222.88, which is well above both its Graham Number ($89.63) and its growth-based Intrinsic Value ($167.76). While the earnings track record is stellar with consistent beats over 25 quarters, bearish insider sentiment and a weak technical trend suggest a potential price correction. The disconnect between the 'Buy' analyst recommendation and a target price ($200.80) that is lower than the current market price further supports a cautious stance.